Table of Content

1 Tumor Necrosis Factor Inhibitor Drug Market Overview
1.1 Product Overview and Scope of Tumor Necrosis Factor Inhibitor Drug
1.2 Tumor Necrosis Factor Inhibitor Drug Segment by Type
1.2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Humira
1.2.3 Enbrel
1.2.4 Remicade
1.2.5 Simponi
1.2.6 Cimzia
1.2.7 Biosimilars
1.3 Tumor Necrosis Factor Inhibitor Drug Segment by Application
1.3.1 Tumor Necrosis Factor Inhibitor Drug Sales Comparison by Application: (2021-2027)
1.3.2 Rheumatoid Arthritis
1.3.3 Psoriatic Arthritis
1.3.4 Juvenile Idiopathic Arthritis
1.3.5 Crohn’s Disease
1.3.6 Ulcerative Colitis
1.3.7 Others
1.4 Global Tumor Necrosis Factor Inhibitor Drug Market Size Estimates and Forecasts
1.4.1 Global Tumor Necrosis Factor Inhibitor Drug Revenue 2016-2027
1.4.2 Global Tumor Necrosis Factor Inhibitor Drug Sales 2016-2027
1.4.3 Tumor Necrosis Factor Inhibitor Drug Market Size by Region: 2016 Versus 2021 Versus 2027

2 Tumor Necrosis Factor Inhibitor Drug Market Competition by Manufacturers
2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Manufacturers (2016-2021)
2.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Tumor Necrosis Factor Inhibitor Drug Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Tumor Necrosis Factor Inhibitor Drug Manufacturing Sites, Area Served, Product Type
2.5 Tumor Necrosis Factor Inhibitor Drug Market Competitive Situation and Trends
2.5.1 Tumor Necrosis Factor Inhibitor Drug Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Tumor Necrosis Factor Inhibitor Drug Players Market Share by Revenue
2.5.3 Global Tumor Necrosis Factor Inhibitor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Tumor Necrosis Factor Inhibitor Drug Retrospective Market Scenario by Region
3.1 Global Tumor Necrosis Factor Inhibitor Drug Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Tumor Necrosis Factor Inhibitor Drug Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Country
3.3.1 North America Tumor Necrosis Factor Inhibitor Drug Sales by Country
3.3.2 North America Tumor Necrosis Factor Inhibitor Drug Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Country
3.4.1 Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country
3.4.2 Europe Tumor Necrosis Factor Inhibitor Drug Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Region
3.5.1 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales by Region
3.5.2 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Country
3.6.1 Latin America Tumor Necrosis Factor Inhibitor Drug Sales by Country
3.6.2 Latin America Tumor Necrosis Factor Inhibitor Drug Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Country
3.7.1 Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country
3.7.2 Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Tumor Necrosis Factor Inhibitor Drug Historic Market Analysis by Type
4.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2016-2021)
4.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2016-2021)
4.3 Global Tumor Necrosis Factor Inhibitor Drug Price by Type (2016-2021)

5 Global Tumor Necrosis Factor Inhibitor Drug Historic Market Analysis by Application
5.1 Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2016-2021)
5.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application (2016-2021)
5.3 Global Tumor Necrosis Factor Inhibitor Drug Price by Application (2016-2021)

6 Key Companies Profiled
6.1 AbbVie Inc.
6.1.1 AbbVie Inc. Corporation Information
6.1.2 AbbVie Inc. Description and Business Overview
6.1.3 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2016-2021)
6.1.4 AbbVie Inc. Product Portfolio
6.1.5 AbbVie Inc. Recent Developments/Updates
6.2 Amgen Inc.
6.2.1 Amgen Inc. Corporation Information
6.2.2 Amgen Inc. Description and Business Overview
6.2.3 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Amgen Inc. Product Portfolio
6.2.5 Amgen Inc. Recent Developments/Updates
6.3 Johnson & Johnson
6.3.1 Johnson & Johnson Corporation Information
6.3.2 Johnson & Johnson Description and Business Overview
6.3.3 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Johnson & Johnson Product Portfolio
6.3.5 Johnson & Johnson Recent Developments/Updates
6.4 UCB
6.4.1 UCB Corporation Information
6.4.2 UCB Description and Business Overview
6.4.3 UCB Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2016-2021)
6.4.4 UCB Product Portfolio
6.4.5 UCB Recent Developments/Updates
6.5 Novartis AG
6.5.1 Novartis AG Corporation Information
6.5.2 Novartis AG Description and Business Overview
6.5.3 Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Novartis AG Product Portfolio
6.5.5 Novartis AG Recent Developments/Updates
6.6 Pfizer, Inc.
6.6.1 Pfizer, Inc. Corporation Information
6.6.2 Pfizer, Inc. Description and Business Overview
6.6.3 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Pfizer, Inc. Product Portfolio
6.6.5 Pfizer, Inc. Recent Developments/Updates
6.7 Merck & Co., Inc.
6.6.1 Merck & Co., Inc. Corporation Information
6.6.2 Merck & Co., Inc. Description and Business Overview
6.6.3 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Merck & Co., Inc. Product Portfolio
6.7.5 Merck & Co., Inc. Recent Developments/Updates
6.8 CASI Pharmaceuticals
6.8.1 CASI Pharmaceuticals Corporation Information
6.8.2 CASI Pharmaceuticals Description and Business Overview
6.8.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2016-2021)
6.8.4 CASI Pharmaceuticals Product Portfolio
6.8.5 CASI Pharmaceuticals Recent Developments/Updates
6.9 EPIRUS Biopharmaceuticals
6.9.1 EPIRUS Biopharmaceuticals Corporation Information
6.9.2 EPIRUS Biopharmaceuticals Description and Business Overview
6.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2016-2021)
6.9.4 EPIRUS Biopharmaceuticals Product Portfolio
6.9.5 EPIRUS Biopharmaceuticals Recent Developments/Updates
6.10 LEO Pharma
6.10.1 LEO Pharma Corporation Information
6.10.2 LEO Pharma Description and Business Overview
6.10.3 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2016-2021)
6.10.4 LEO Pharma Product Portfolio
6.10.5 LEO Pharma Recent Developments/Updates
6.11 PROBIOMED
6.11.1 PROBIOMED Corporation Information
6.11.2 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Description and Business Overview
6.11.3 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2016-2021)
6.11.4 PROBIOMED Product Portfolio
6.11.5 PROBIOMED Recent Developments/Updates
6.12 Shanghai Pharmaceuticals Holding Co., Ltd.
6.12.1 Shanghai Pharmaceuticals Holding Co., Ltd. Corporation Information
6.12.2 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Description and Business Overview
6.12.3 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Shanghai Pharmaceuticals Holding Co., Ltd. Product Portfolio
6.12.5 Shanghai Pharmaceuticals Holding Co., Ltd. Recent Developments/Updates

7 Tumor Necrosis Factor Inhibitor Drug Manufacturing Cost Analysis
7.1 Tumor Necrosis Factor Inhibitor Drug Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitor Drug
7.4 Tumor Necrosis Factor Inhibitor Drug Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Tumor Necrosis Factor Inhibitor Drug Distributors List
8.3 Tumor Necrosis Factor Inhibitor Drug Customers

9 Tumor Necrosis Factor Inhibitor Drug Market Dynamics
9.1 Tumor Necrosis Factor Inhibitor Drug Industry Trends
9.2 Tumor Necrosis Factor Inhibitor Drug Growth Drivers
9.3 Tumor Necrosis Factor Inhibitor Drug Market Challenges
9.4 Tumor Necrosis Factor Inhibitor Drug Market Restraints

10 Global Market Forecast
10.1 Tumor Necrosis Factor Inhibitor Drug Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Tumor Necrosis Factor Inhibitor Drug by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Tumor Necrosis Factor Inhibitor Drug by Type (2022-2027)
10.2 Tumor Necrosis Factor Inhibitor Drug Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Tumor Necrosis Factor Inhibitor Drug by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Tumor Necrosis Factor Inhibitor Drug by Application (2022-2027)
10.3 Tumor Necrosis Factor Inhibitor Drug Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Tumor Necrosis Factor Inhibitor Drug by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Tumor Necrosis Factor Inhibitor Drug by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Tumor Necrosis Factor Inhibitor Drug Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Tumor Necrosis Factor Inhibitor Drug Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Tumor Necrosis Factor Inhibitor Drug Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Tumor Necrosis Factor Inhibitor Drug Covered in This Study
Table 5. Global Tumor Necrosis Factor Inhibitor Drug Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Tumor Necrosis Factor Inhibitor Drug Sales Share by Manufacturers (2016-2021)
Table 7. Global Tumor Necrosis Factor Inhibitor Drug Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Tumor Necrosis Factor Inhibitor Drug Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Tumor Necrosis Factor Inhibitor Drug Average Price (US$/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Tumor Necrosis Factor Inhibitor Drug Manufacturing Sites and Area Served
Table 11. Manufacturers Tumor Necrosis Factor Inhibitor Drug Product Type
Table 12. Global Tumor Necrosis Factor Inhibitor Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Tumor Necrosis Factor Inhibitor Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor Necrosis Factor Inhibitor Drug as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Tumor Necrosis Factor Inhibitor Drug Sales by Region (2016-2021) & (K Units)
Table 16. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region (2016-2021)
Table 17. Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2016-2021) & (K Units)
Table 19. North America Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2016-2021)
Table 20. North America Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2016-2021)
Table 22. Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country (2016-2021) & (K Units)
Table 23. Europe Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2016-2021)
Table 24. Europe Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Region (2016-2021)
Table 30. Latin America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2016-2021)
Table 32. Latin America Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2016-2021)
Table 38. Global Tumor Necrosis Factor Inhibitor Drug Sales (K Units) by Type (2016-2021)
Table 39. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2016-2021)
Table 40. Global Tumor Necrosis Factor Inhibitor Drug Revenue (Million US$) by Type (2016-2021)
Table 41. Global Tumor Necrosis Factor Inhibitor Drug Revenue Share by Type (2016-2021)
Table 42. Global Tumor Necrosis Factor Inhibitor Drug Price (US$/Unit) by Type (2016-2021)
Table 43. Global Tumor Necrosis Factor Inhibitor Drug Sales (K Units) by Application (2016-2021)
Table 44. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2016-2021)
Table 45. Global Tumor Necrosis Factor Inhibitor Drug Revenue (Million US$) by Application (2016-2021)
Table 46. Global Tumor Necrosis Factor Inhibitor Drug Revenue Share by Application (2016-2021)
Table 47. Global Tumor Necrosis Factor Inhibitor Drug Price (US$/Unit) by Application (2016-2021)
Table 48. AbbVie Inc. Corporation Information
Table 49. AbbVie Inc. Description and Business Overview
Table 50. AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 51. AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product
Table 52. AbbVie Inc. Recent Developments/Updates
Table 53. Amgen Inc. Corporation Information
Table 54. Amgen Inc. Description and Business Overview
Table 55. Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 56. Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product
Table 57. Amgen Inc. Recent Developments/Updates
Table 58. Johnson & Johnson Corporation Information
Table 59. Johnson & Johnson Description and Business Overview
Table 60. Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 61. Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product
Table 62. Johnson & Johnson Recent Developments/Updates
Table 63. UCB Corporation Information
Table 64. UCB Description and Business Overview
Table 65. UCB Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 66. UCB Tumor Necrosis Factor Inhibitor Drug Product
Table 67. UCB Recent Developments/Updates
Table 68. Novartis AG Corporation Information
Table 69. Novartis AG Description and Business Overview
Table 70. Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 71. Novartis AG Tumor Necrosis Factor Inhibitor Drug Product
Table 72. Novartis AG Recent Developments/Updates
Table 73. Pfizer, Inc. Corporation Information
Table 74. Pfizer, Inc. Description and Business Overview
Table 75. Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 76. Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product
Table 77. Pfizer, Inc. Recent Developments/Updates
Table 78. Merck & Co., Inc. Corporation Information
Table 79. Merck & Co., Inc. Description and Business Overview
Table 80. Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 81. Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product
Table 82. Merck & Co., Inc. Recent Developments/Updates
Table 83. CASI Pharmaceuticals Corporation Information
Table 84. CASI Pharmaceuticals Description and Business Overview
Table 85. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 86. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product
Table 87. CASI Pharmaceuticals Recent Developments/Updates
Table 88. EPIRUS Biopharmaceuticals Corporation Information
Table 89. EPIRUS Biopharmaceuticals Description and Business Overview
Table 90. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 91. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product
Table 92. EPIRUS Biopharmaceuticals Recent Developments/Updates
Table 93. LEO Pharma Corporation Information
Table 94. LEO Pharma Description and Business Overview
Table 95. LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 96. LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product
Table 97. LEO Pharma Recent Developments/Updates
Table 98. PROBIOMED Corporation Information
Table 99. PROBIOMED Description and Business Overview
Table 100. PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 101. PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product
Table 102. PROBIOMED Recent Developments/Updates
Table 103. Shanghai Pharmaceuticals Holding Co., Ltd. Corporation Information
Table 104. Shanghai Pharmaceuticals Holding Co., Ltd. Description and Business Overview
Table 105. Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 106. Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product
Table 107. Shanghai Pharmaceuticals Holding Co., Ltd. Recent Developments/Updates
Table 108. Production Base and Market Concentration Rate of Raw Material
Table 109. Key Suppliers of Raw Materials
Table 110. Tumor Necrosis Factor Inhibitor Drug Distributors List
Table 111. Tumor Necrosis Factor Inhibitor Drug Customers List
Table 112. Tumor Necrosis Factor Inhibitor Drug Market Trends
Table 113. Tumor Necrosis Factor Inhibitor Drug Growth Drivers
Table 114. Tumor Necrosis Factor Inhibitor Drug Market Restraints
Table 115. Global Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Type (2022-2027) & (K Units)
Table 116. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share Forecast by Type (2022-2027)
Table 117. Global Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 118. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share Forecast by Type (2022-2027)
Table 119. Global Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Application (2022-2027) & (K Units)
Table 120. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share Forecast by Application (2022-2027)
Table 121. Global Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 122. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share Forecast by Application (2022-2027)
Table 123. Global Tumor Necrosis Factor Inhibitor Drug Sales Forecast by Region (2022-2027) & (K Units)
Table 124. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share Forecast by Region (2022-2027)
Table 125. Global Tumor Necrosis Factor Inhibitor Drug Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 126. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share Forecast by Region (2022-2027)
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Tumor Necrosis Factor Inhibitor Drug
Figure 2. Global Tumor Necrosis Factor Inhibitor Drug Market Share by Type in 2020 & 2027
Figure 3. Humira Product Picture
Figure 4. Enbrel Product Picture
Figure 5. Remicade Product Picture
Figure 6. Simponi Product Picture
Figure 7. Cimzia Product Picture
Figure 8. Biosimilars Product Picture
Figure 9. Global Tumor Necrosis Factor Inhibitor Drug Market Share by Application in 2020 & 2027
Figure 10. Rheumatoid Arthritis
Figure 11. Psoriatic Arthritis
Figure 12. Juvenile Idiopathic Arthritis
Figure 13. Crohn’s Disease
Figure 14. Ulcerative Colitis
Figure 15. Others
Figure 16. Global Tumor Necrosis Factor Inhibitor Drug Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 17. Global Tumor Necrosis Factor Inhibitor Drug Market Size 2016-2027 (US$ Million)
Figure 18. Global Tumor Necrosis Factor Inhibitor Drug Sales 2016-2027 (K Units)
Figure 19. Global Tumor Necrosis Factor Inhibitor Drug Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 20. Tumor Necrosis Factor Inhibitor Drug Sales Share by Manufacturers in 2020
Figure 21. Global Tumor Necrosis Factor Inhibitor Drug Revenue Share by Manufacturers in 2020
Figure 22. The Global 5 and 10 Largest Tumor Necrosis Factor Inhibitor Drug Players: Market Share by Revenue in 2020
Figure 23. Tumor Necrosis Factor Inhibitor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 24. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region (2016-2021)
Figure 25. Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region in 2020
Figure 26. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Region (2016-2021)
Figure 27. Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Region in 2020
Figure 28. U.S. Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Canada Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Germany Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. France Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. U.K. Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Italy Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Russia Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. China Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Japan Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. South Korea Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. India Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Australia Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Taiwan Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Indonesia Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Thailand Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Malaysia Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Philippines Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Vietnam Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Mexico Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Brazil Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Argentina Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 49. Turkey Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 50. Saudi Arabia Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 51. UAE Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 52. Sales Market Share of Tumor Necrosis Factor Inhibitor Drug by Type (2016-2021)
Figure 53. Sales Market Share of Tumor Necrosis Factor Inhibitor Drug by Application (2016-2021)
Figure 54. Sales Market Share of Tumor Necrosis Factor Inhibitor Drug by Application in 2020
Figure 55. Revenue Share of Tumor Necrosis Factor Inhibitor Drug by Application (2016-2021)
Figure 56. Revenue Share of Tumor Necrosis Factor Inhibitor Drug by Application in 2020
Figure 57. Manufacturing Cost Structure of Tumor Necrosis Factor Inhibitor Drug
Figure 58. Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitor Drug
Figure 59. Tumor Necrosis Factor Inhibitor Drug Industrial Chain Analysis
Figure 60. Channels of Distribution
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed